Mankind Pharma Limited — Investor Meet, 11-11-2024: Analysts/Institutional Investor Meet/Con. Call Updates

1. Financial Performance: Mankind Pharma reported Q2 FY25 revenue of INR 3,077 crores, marking a 14% year-on-year growth. The EBITDA for the quarter surged by 24.3% to INR 853 crores, yielding a margin improvement to 27.7%. The first half of FY25 witnessed a 13% revenue increase. The chronic segment's share rose to 36% from 34.8% year-on-year, reflecting robust performance in cardiac and anti-diabetic treatments. The company reported a PAT of INR 659 crores, resulting in a diluted EPS of INR 16.3.

2. Future Outlook and Growth Drivers: Management highlighted the strategic acquisition of Bharat Serums and Vaccines Limited, aiming to expand its footprint in specialized healthcare, particularly women's health. Plans to launch multiple products and enhance its product pipeline showcase the company’s commitment to innovation. The consumer healthcare segment has been carved out into a subsidiary, anticipating robust growth fueled by increased online sales channels.

3. Order Book and Operational Updates: The domestic business revenue increased by 11% to INR 2,796 crores, supported by strong volume growth. The newly launched Crenzlo injection has added to the chronic therapy offerings. Additionally, the Consumer Healthcare segment saw a 20% revenue rise, driven by key brand growth and e-commerce advancements.

4. Analyst Q&A Insights (Detailed):

- **Revenue and Profitability:** Analysts sought insights into revenue forecasts and operational efficiencies, with management emphasizing growth in chronic and specialized therapies.

- **Market Position and Competitive Landscape:** Management expressed confidence in Mankind's market positioning amidst rising competition and regulatory challenges in acute products.

- **Operational Challenges or Risks:** Addressed supply chain pressures with optimistic strategies to mitigate risks, particularly post-acquisition integration.

- **Capex and Capital Allocation:** Queries about capital deployment were met with reassurances about maintaining a net debt-to-EBITDA ratio below 2x, focusing on sustainable growth.

- **Strategic Priorities and Long-Term Vision:** Analysts probed long-term initiatives, with management optimistic about leveraging the synergies from BSV to bolster both domestic and international growth.

5. Market or Regulatory Updates: The management addressed recent regulatory developments affecting product pricing, specifically for emergency contraceptives, noting price adjustments and ongoing market strategies.

6. Strategic Focus Areas: A noticeable emphasis on expanding the chronic portfolio and enhancing product innovation through strategic acquisitions positions Mankind favorably for sustained growth. The company is poised to leverage emerging healthcare needs, focusing on both organic and inorganic growth.

7. Investor Insight: The financial health and proactive strategic initiatives present a favorable outlook. The potential for long-term growth in chronic therapies and recovery in OTC segments underpin a ‘buy’ stance, considering the company’s strong fundamentals and market positioning in a competitive landscape.